ALK and non-small cell lung carcinoma: Recent CNS metastases consensus guidelines published by ASCO/ASTRO recommend consideration of upfront TKI for NSCLC with brain metastases in the setting of EGFR and ALK alterations but do not comment on the use of TKIs for other targetable alterations [12].